Randomized Trialvery high evidence
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.
The lancet. Diabetes & endocrinology·May 11, 2026·PMID 42114520
Why it mattersThis head-to-head analysis provides direct evidence that tirzepatide offers greater kidney protection than dulaglutide, a GLP-1 receptor agonist already shown to reduce kidney events. It helps clinicians weigh the renal benefits of dual incretin agonism in a high-risk population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled